CCIA
JAZZ icon

Campbell & Co Investment Adviser’s Jazz Pharmaceuticals JAZZ Stock Holding History

Campbell & Co Investment Adviser’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$681K Buy
+3,602
New +$630K 0.04% 646
2025
Q2 		– Sell
-29,592
Closed -$3.67M – 1286
2025
Q1 		$3.67M Buy
+29,592
New +$3.86M 0.28% 70
2024
Q4 		– Sell
-11,945
Closed -$1.33M – 1201
2024
Q3 		$1.33M Buy
11,945
+3,557
+42% +$390K 0.1% 328
2024
Q2 		$895K Buy
8,388
+4,975
+146% +$547K 0.08% 407
2024
Q1 		$411K Sell
3,413
-7,765
-69% -$951K 0.04% 789
2023
Q4 		$1.37M Buy
11,178
+414
+4% +$51.7K 0.12% 250
2023
Q3 		$1.39M Buy
10,764
+8,078
+301% +$1.08M 0.17% 169
2023
Q2 		$333K Buy
+2,686
New +$361K 0.06% 617
2023
Q1 		– Sell
-8,041
Closed -$1.28M – 922
2022
Q4 		$1.28M Sell
8,041
-794
-9% -$116K 0.31% 52
2022
Q3 		$1.18M Buy
8,835
+4,118
+87% +$626K 0.27% 94
2022
Q2 		$736K Buy
+4,717
New +$726K 0.2% 155
2021
Q4 		– Sell
-4,491
Closed -$585K – 714
2021
Q3 		$585K Buy
+4,491
New +$679K 0.19% 170
2020
Q1 		– Sell
-1,494
Closed -$223K – 270
2019
Q4 		$223K Sell
1,494
-3,518
-70% -$479K 0.07% 542
2019
Q3 		$642K Buy
+5,012
New +$672K 0.24% 108
2019
Q2 		– Sell
-2,124
Closed -$304K – 610
2019
Q1 		$304K Buy
+2,124
New +$277K 0.15% 269
2018
Q4 		– Sell
-1,567
Closed -$263K – 415
2018
Q3 		$263K Buy
+1,567
New +$269K 0.18% 265
2016
Q3 		– Sell
-1,822
Closed -$257K – 165
2016
Q2 		$257K Buy
+1,822
New +$269K 1.3% 30
2015
Q4 		– Sell
-2,755
Closed -$366K – 149
2015
Q3 		$366K Buy
+2,755
New +$474K 0.24% 150
2015
Q1 		– Sell
-5,500
Closed -$901K – 238
2014
Q4 		$901K Buy
+5,500
New +$913K 0.55% 64
2014
Q1 		– Sell
-9,192
Closed -$1.16M – 249
2013
Q4 		$1.16M Buy
+9,192
New +$951K 0.26% 117

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Campbell & Co Investment Adviser's JAZZ Position: Q1 2026 in Review

Campbell & Co Investment Adviser opened a new position in Jazz Pharmaceuticals (JAZZ) in Q1 2026: 3,602 shares worth $681K. The stake represents 0.04% of the portfolio and ranks #646 among its holdings. This is a return to the name: Campbell & Co Investment Adviser previously reported a position in JAZZ as recently as Q1 2025.

Campbell & Co Investment Adviser first reported a position in JAZZ in Q4 2013 and has held it in 20 quarters since. The position peaked at $3.67M in Q1 2025. 571 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Campbell & Co Investment Adviser held 3,602 shares of Jazz Pharmaceuticals worth $681K as of Q1 2026.
  • Jazz Pharmaceuticals was a new Campbell & Co Investment Adviser position in Q1 2026.
  • Jazz Pharmaceuticals made up 0.04% of Campbell & Co Investment Adviser's portfolio in Q1 2026, its #646 holding.
  • Campbell & Co Investment Adviser first reported a position in Jazz Pharmaceuticals in Q4 2013 and has held it in 20 quarters since.
  • Campbell & Co Investment Adviser's Jazz Pharmaceuticals position peaked at $3.67M in Q1 2025.
  • 571 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q1 2026, filed 15 May 2026.